Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

ECI830

Name: ECI830
Brand: TargetMol
SKU: T204836
Rating: 4.5 (1 reviews)

Copy Product Info

🥰Excellent

Synonyms:

Catalog No. T204836 Copy Product Info

🥰Excellent

ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. By inhibiting CDK2 activity, ECI830 induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for use in studies of HR+/HER2- breast cancer and tumors with CCNE1 amplification.

Cas No. 3054692-62-2

Pack Size	Price	USA Stock	Global Stock
1 mg	$283	10-14 weeks	10-14 weeks
5 mg	$676	10-14 weeks	10-14 weeks
25 mg	$1,550	10-14 weeks	10-14 weeks
100 mg	$3,380	10-14 weeks	10-14 weeks

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Resource Download

Product Introduction

Bioactivity

Description	ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. By inhibiting CDK2 activity, ECI830 induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for use in studies of HR+/HER2- breast cancer and tumors with CCNE1 amplification.
In vitro	ECI830 demonstrated significant antiproliferative activity in CCNE1-amplified ovarian cancer cell lines (OVCAR3) and lung cancer cell lines (H810). [1] The combination of ECI830 and ribociclib produced a synergistic effect in HR+/HER2– breast cancer cells, effectively inhibiting cell growth. [2]
In vivo	In a xenograft model of HR+/HER2- breast cancer cell line (MCF7) resistant to standard therapy, the combination of ECI830 and ribociclib exhibited synergistic effects, significantly inhibiting tumor growth. [1] Treatment with ECI830 in combination with ribociclib significantly regulated pRB1 in HR+/HER2⁻ breast cancer CDX and PDX models, demonstrating potent antitumor activity. ECI830 monotherapy effectively inhibited tumor growth in CCNE1-amplified tumor models.[2]

Chemical Properties

Molecular Weight	384.43
Formula	C₁₉H₂₄N₆O₃
Cas No.	3054692-62-2
Smiles	O=C1C2(C=3C(N1[C@H]4C[C@H](O)CCC4)=NC(NC=5C(OCC)=NNC5)=NC3)CC2

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Related Tags: ECI830 chemical structure | ECI830 in vivo | ECI830 in vitro | ECI830 formula | ECI830 molecular weight